Immix Biopharma

Immix Biopharma's additional NXC-201 clinical data for relapsed/refractory AL Amyloidosis will be presented at the 20th International Myeloma Society Annual Meeting in Athens, Greece, September 27-30, 2023. Dr. Polina Stepensky highlighted progress in providing new treatment options for patients.

Nexcella, Inc. announced updated NXC-201 clinical data for relapsed/refractory multiple myeloma will be presented at the 20th International Myeloma Society Annual Meeting in Athens, Greece. NXC-201, a BCMA-targeted CAR-T cell therapy, shows promise in treating multiple myeloma and AL amyloidosis, with ongoing Phase 1b/2a trials aiming for FDA submission.

Immix Biopharma focuses on CAR-T cell therapy for AL Amyloidosis, autoimmune diseases, and multiple myeloma, with NXC-201 in Phase Ib/IIa trials. IMX-110, in trials for advanced solid tumors, combines with tislelizumab for CRC, utilizing TME Normalization technology for mCRC and STS.

Nexcella, Inc., a subsidiary of Immix Biopharma, completed a Pre-IND meeting with the FDA for NXC-201, targeting AL amyloidosis and multiple myeloma. The meeting discussed US manufacturing and clinical trials, aiming for regulatory clarity to proceed with an IND application. NXC-201, a BCMA-targeted CAR-T cell therapy, has shown promising response rates in ongoing trials.

Immix Biopharma completed a $5M ATM equity offering, selling 2,263,868 shares. Funds will support IMX-110 clinical trials and general corporate purposes. The company focuses on CAR-T cell therapies and TSTx for oncology and immuno-dysregulated diseases, with NXC-201 as a leading outpatient CAR-T therapy.

Nexcella, Inc. announced the publication of an editorial in Haematologica highlighting NXC-201, a BCMA CAR-T cell therapy, showing a 75% overall response rate in multiple myeloma patients. The therapy demonstrated a good safety profile and potential for outpatient treatment. NXC-201 is also being studied for AL amyloidosis, with promising early results.

Nexcella, Inc., a subsidiary of Immix Biopharma, has dosed 50 relapsed/refractory multiple myeloma patients with CAR-T therapy NXC-201 in a Phase 1b/2a trial, aiming for FDA approval. The trial shows a 90% overall response rate in multiple myeloma and 100% in AL amyloidosis. Nexcella plans to present data and enroll 100 patients, highlighting significant progress towards BLA submission.